Clinical trials: in Jordan
Diabetes Mellitus, Type 2
An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa
The study is intended to estimate the proportion and clinical management of people with type 2 diabetes having atherosclerotic cardiovascular diseases or who are at high risk to develop atherosclerotic cardiovascular diseases.
- Trial name
- PACT-MEA (NCT05317845)
- Testing
- No treatment given
- Where
- 7 sites in Bahrain, Egypt and 5 more
- Volunteers
- 4,089 people
- Sponsor
- Novo Nordisk A/S
Hypercholesterolemia
Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD)…
- Trial name
- NCT03175367
- Testing
- Evinacumab, Background Lipid Modifying Therapy (LMT)
- Where
- 95 sites in United States, Australia and 18 more
- Volunteers
- 272 people
- Sponsor
- Regeneron Pharmaceuticals
Pediatric Heart Failure
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure
This study consists of two parts (Part 1 and Part 2). The purpose of Part 1 is to evaluate the way the body absorbs, distributes, metabolizes and removes the drug LCZ696.
- Trial name
- NCT02678312
- Testing
- LCZ696, Enalapril
- Where
- 98 sites in United States, Argentina and 27 more
- Volunteers
- 393 people
- Sponsor
- Novartis Pharmaceuticals
Bioequivalence, Healthy Subjects
Bioequivalence Study of Test and Reference 50 mg Eplerenone Film-coated Tablets in Healthy Volunteers
This study is a comparative bioavailability study performed to assess bioequivalence between Test medicinal product (Efez 50 mg eplerenone film-coated tablets manufactured by PrJSC "Pharmaceutical firm "Darnitsa", Ukraine) and…
- Trial name
- NCT05663372
- Testing
- Efez 50 mg eplerenone film-coated tablets, INSPRA® 50 mg eplerenone film-coated tablets
- Where
- Jordan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Darnitsa Pharmaceutical Company
Bioequivalence, Healthy Subjects
Bioequivalence Study of Test and Reference 400 mg Ibuprofen Coated Tablets in Healthy Volunteers
This study is a comparative bioavailability study performed to assess bioequivalence between Test medicinal product (Darfen 400, 400 mg ibuprofen coated tablets [512 mg ibuprofen sodium dihydrate], manufactured by PrJSC…
- Trial name
- NCT05663398
- Testing
- Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate), Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
- Where
- Jordan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Darnitsa Pharmaceutical Company
Diabetic Nephropathy
Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Nidufexor addresses fibrosis, oxidative stress, inflammation and cell death, and therefore has the potential to improve the management of diabetic kidney disease when added to the standard of care (SoC) (angiotensin converting…
- Trial name
- NCT03804879
- Testing
- Nidufexor, Standard of Care (SoC)
- Where
- 18 sites in United States, Argentina and 5 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Bioequivalence, Healthy Subjects
Bioequivalence Study of 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide / 10 mg Amlodipine Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide / 10 mg Amlodipine Film-Coated Tablets in Healthy Volunteers
The present study is a comparative bioavailability study performed to assess bioequivalence between a Test medication (PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets…
- Trial name
- NCT05470764
- Testing
- PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets, TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets
- Where
- Jordan
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Darnitsa Pharmaceutical Company
Bioequivalence, Healthy Subjects
Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers
The present study is a comparative bioavailability study performed to assess bioequivalence between a Test medication (PERINDOPRES® DUO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets manufactured by PrJSC…
- Trial name
- NCT05464745
- Testing
- PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets, Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets
- Where
- Jordan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Darnitsa Pharmaceutical Company
Type 2 Diabetes Mellitus
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings
DISCOVER is a Non Interventional Study study to describe the disease management patterns and clinical evolution over three years in type 2 diabetes mellitus patients initiating a second line anti-diabetic treatment.
- Trial name
- DISCOVER (NCT02322762)
- Where
- 303 sites in Algeria, Argentina and 30 more
- Volunteers
- 15,992 people
- Sponsor
- AstraZeneca
Diabetes
Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.
Primary Objective: Assess effectiveness of insulin glargine (U300) in achieving glycemic goal measured by hemoglobin A1c (HbA1c).
- Trial name
- ATOS (NCT03703869)
- Testing
- Insulin glargine (U300)
- Where
- 388 sites in Colombia, Egypt and 16 more
- Volunteers
- 4,589 people
- Sponsor
- Sanofi
Type 2 Diabetes
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (both administered in combination with other anti-diabetic drugs) based on the change in HbA1c from baseline to 24 weeks
- Trial name
- INSTRIDE 2 (NCT02227875)
- Testing
- Mylan's insulin glargine, Lantus®
- Where
- 120 sites in United States, Jordan and 4 more
- Volunteers
- 560 people
- Sponsor
- Mylan Inc.
Pharmacokinetics
Fasting Bioequivalence Study of 2 Progesterone Soft Capsules 200 mg in 66 Healthy Female Subjects Under Vaginal Route
This study was designed to assess the bioequivalence of Progesterone 200 mg Soft Capsule (JSC "Farmak", Ukraine) versus Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins…
- Trial name
- NCT05125627
- Testing
- Progesterone 200 mg Soft Capsule (JSC "Farmak", Ukraine), Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
- Where
- Jordan
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Joint Stock Company "Farmak"
Pharmacokinetics
Fasting Bioequivalence Study of 2 Oral Progesterone Soft Capsules 200 mg in 48 Healthy Female Subjects
This study was designed to assess the bioequivalence of single oral dose of Progesterone 200 mg Soft Capsule (JSC "Farmak", Ukraine) Versus Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH…
- Trial name
- NCT05125640
- Testing
- Progesterone 200 mg Soft Capsule (JSC "Farmak", Ukraine), Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
- Where
- Jordan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Joint Stock Company "Farmak"
Arthritis, Rheumatoid
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with…
- Trial name
- NCT02092467
- Testing
- tofacitinib, adalimumab, etanercept
- Where
- 345 sites in United States, Argentina and 28 more
- Volunteers
- 4,372 people
- Sponsor
- Pfizer
Hereditary Angioedema (HAE)
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.
- Trial name
- NCT02741596
- Testing
- DX-2930
- Where
- 43 sites in United States, Canada and 5 more
- Volunteers
- 212 people
- Sponsor
- Shire
Hereditary Angioedema (HAE)
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
The purpose of this study is to evaluate the efficacy and safety of repeated doses of ecallantide in the treatment of acute attacks of hereditary angioedema and to allow HAE patients continued access to ecallantide.
- Trial name
- NCT00456508
- Testing
- ecallantide
- Where
- 41 sites in United States, Canada and 1 more
- Volunteers
- 147 people
- Sponsor
- Shire
Hereditary Angioedema (HAE)
Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)
The purpose of this study is to evaluate the efficacy and safety of DX-88 (ecallantide) versus placebo in the treatment of moderate to severe acute attacks of hereditary angioedema.
- Trial name
- NCT00457015
- Testing
- ecallantide, Phosphate Buffer Saline (PBS), pH 7.0
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- Shire
Hereditary Angioedema (HAE)
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
- Trial name
- NCT02586805
- Testing
- DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk
- Where
- 41 sites in United States, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- Shire
Hereditary Angioedema (HAE)
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of multiple subcutaneous administrations of DX-2930 across a range of doses in HAE participants.
- Trial name
- NCT02093923
- Testing
- DX-2930
- Where
- 14 sites in United States, Italy and 1 more
- Volunteers
- 38 people
- Sponsor
- Shire
Coronary Artery Disease
EXCELLA Post-Approval Study
To evaluate long-term safety and performance of the DESyne Novolimus Eluting Coronary Stent System and the DESyne BD Novolimus Eluting Coronary Stent System
- Trial name
- NCT02009956
- Testing
- Subjects receiving DESyne Novolimus Eluting CSS
- Where
- 4 sites in Germany, Jordan and 1 more
- Volunteers
- 57 people
- Sponsor
- Elixir Medical Corporation